Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers examine current treatments for aggressive colorectal cancer

NCT ID NCT04317599

Knowledge-focused Sponsor: Pierre Fabre Medicament Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at medical records of 274 people with a specific type of advanced colorectal cancer (BRAF V600E mutation) to see what treatments they received and how well they worked. The goal was to understand real-world treatment patterns and outcomes, since there is no standard targeted therapy for this group. The study did not test new treatments but gathered information to help guide future research and healthcare decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

274 people

The number who actually took part.

Started

Apr 2020

Finished

May 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with BRAFV600E mutant mCRC (determined by local laboratory result) in the target countries and initiating first line treatment between January 1st, 2016 and December 31st, 2018 (both days inclusive) will be eligible for enrollment into the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of histologically or cytologically confirmed CRC that is metastatic and unresectable * Presence of BRAFV600E mutation in tumor tissue, as confirmed by a local assay * Initiated first-line treatment with drugs registered for mCRC in the respective country at the time of treatment between January 1st, 2016 and December 31st, 2018 (both days inclusive) * Provision of informed consent or non-opposition to the patient (or next of kin, if applicable) for the use of data, according to local regulations Exclusion Criteria: Patients will be excluded from the study if they fulfil any of the following criteria: * Patients with another concomitant cancer at the time of diagnosis\* * Patients participating in interventional trials on investigational drugs at the time of initiation of first-line treatment * Except for non-metastatic non-melanoma skin cancers, or in situ or benign neoplasms; a cancer will be considered concomitant if it occurs within 5 years of mCRC diagnosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600E mutation positive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF V600E mutation positive Metastatic colorectal cancer

Contacts and locations

Locations

  • AUSL-IRCCS of Reggio Emilia-Clinical Cancer Center

    Reggio Emilia, Italy

  • AZ Klina

    Brasschaat, Belgium

  • Asst Valle Olona

    Saronno, Italy

  • Azienda Ospedaliero-Universitaria Pisana

    Pisa, Italy

  • Barmherzige Brüder Krankenhaus St. Veit/Glan.

    Saint Veit/Glan, Austria

  • CHC MontLégia

    Liège, Belgium

  • CHRU de Besançon

    Besançon, France

  • CHU Grenoble Alpes

    La Tronche, France

  • CHU de Poitiers

    Poitiers, France

  • Centre Oscar Lambert

    Lille, France

  • Clinica Oncologica Ospedali Riuniti di Ancona

    Ancona, Italy

  • Facharztzentrum Eppendorf

    Hamburg, Germany

  • GHPSO (Groupe Hospitalier Sud de l'Oise)

    Creil, France

  • Gustave Roussy

    Villejuif, France

  • Harrogate & District NHS Foundation Trust

    Harrogate, United Kingdom

  • Hospital General Universitario de Valencia

    Valencia, Spain

  • Hospital del Mar

    Barcelona, Spain

  • Hôpital Franco-Britannique

    Levallois-Perret, France

  • ICM Val d'Aurelle

    Montpellier, France

  • Imelda VZW

    Bonheiden, Belgium

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Instituto Nazionale Tumori, IRCCS, Fondazione G. Pascale

    Naples, Italy

  • Klinikum Aschaffenburg Medical Klinik IV

    Aschaffenburg, Germany

  • La Paz University Hospital

    Madrid, Spain

  • MVZ Mitte Leipzig

    Leipzig, Germany

  • MZ Onkologie Velbert/Ratingen/Mettmann

    Velbert, Germany

  • Medizinische Universität Wien

    Vienna, Austria

  • Oncoresearch Lerchenfeld

    Hamburg, Germany

  • Santa Maria Goretti Hospital

    Latina, Italy

  • Studienzentrale Gokos

    Dresden, Germany

  • UZ Leuven

    Leuven, Belgium

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Universitätsklinikum Essen

    Essen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.